Ashleigh Palmer - Provention Bio CEO, Co-Founder
| PRVBDelisted Stock | USD 24.98 0.00 0.00% |
CEO
Mr. Ashleigh Palmer is President, Chief Executive Officer, Director of the Company. He is a life sciences industry entrepreneur and innovator with more than 30 years experience and expertise in corporate strategy formulation, preclinical and clinical drug evaluation and product development and commercialization. During his career, Mr. Palmer has served as CEO for multiple biopharma companies and has held numerous board director and chairman positions. In addition to leading Provention, Mr. Palmer currently serves as Chairman of Celimmune, LLC, a clinical stage immunotherapy company dedicated to developing transformational therapies for celiac disease and other serious immunemediated diseases, and as a nonexecutive director of Third Pole, a clinicalstage biopharmaceutical company developing electric generated inhaled nitric oxide
| Age | 54 |
| Professional Marks | MBA |
| Phone | 908 336 0360 |
| Web | https://www.proventionbio.com |
Provention Bio Management Efficiency
The company has return on total asset (ROA) of (0.4301) % which means that it has lost $0.4301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9766) %, meaning that it created substantial loss on money invested by shareholders. Provention Bio's management efficiency ratios could be used to measure how well Provention Bio manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 23.47 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Provention Bio has a current ratio of 3.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Provention Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Provention Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provention Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provention to invest in growth at high rates of return. When we think about Provention Bio's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 12 records | CEO Age | ||
| Cedric Francois | Apellis Pharmaceuticals | 45 | |
| Andy Deig | ImmunovantInc | N/A | |
| Lonnel Coats | Lexicon Pharmaceuticals | 59 | |
| Eric MBA | Seres Therapeutics | 48 | |
| Brian Lian | Viking Therapeutics | 58 | |
| Chen Schor | Madrigal Pharmaceuticals | 41 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Andrew MD | Akero Therapeutics | 57 | |
| Michael Raab | Ardelyx | 59 | |
| Kinneret Savitsky | BioLineRx | 48 | |
| Richard Adcock | Immunitybio | 55 | |
Management Performance
| Return On Equity | -0.98 | |||
| Return On Asset | -0.43 |
Provention Bio Leadership Team
Elected by the shareholders, the Provention Bio's board of directors comprises two types of representatives: Provention Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Provention. The board's role is to monitor Provention Bio's management team and ensure that shareholders' interests are well served. Provention Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Provention Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Levine, VP Marketing | ||
| Sarah OBrien, Chief Officer | ||
| Wayne Pisano, Independent Director | ||
| Andrew Drechsler, CFO | ||
| Robert Doody, VP Relations | ||
| Eleanor MD, Chief Officer | ||
| Thierry Chauche, Chief Officer | ||
| Joshua Drumm, IR Contact Officer | ||
| LLM JD, Chief Officer | ||
| Ashleigh Palmer, CEO, Co-Founder | ||
| Francisco Leon, Co-Founder, Chief Scientific Officer | ||
| Avery Catlin, Director | ||
| Cameron Gray, Independent Director | ||
| Kaelan Hollon, VP Communications | ||
| Francisco MD, CoFounder Officer | ||
| Anthony DiGiandomenico, Independent Director | ||
| Eleanor Ramos, COO,Chief Medical Officer | ||
| Jeffrey Bluestone, Director | ||
| Christina Yi, Chief Officer |
Provention Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Provention Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.98 | |||
| Return On Asset | -0.43 | |||
| Operating Margin | (9.94) % | |||
| Current Valuation | 607.28 M | |||
| Shares Outstanding | 91.1 M | |||
| Shares Owned By Insiders | 4.61 % | |||
| Shares Owned By Institutions | 53.20 % | |||
| Number Of Shares Shorted | 5.37 M | |||
| Price To Book | 5.31 X | |||
| Price To Sales | 289.70 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Provention Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Provention Stock
If you are still planning to invest in Provention Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provention Bio's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |